Pioneers in NETosis

Anthony is a biotechnology executive and life sciences investor with expertise spanning all stages of pharmaceutical development in various therapeutic areas, corporate governance, and financial transactions. He concurrently serves as Investor at Morningside, where he has deployed more than $250M across 15+ portfolio companies and served as board chairman, director, and observer across more than a dozen life sciences companies. Prior to his investment career, Anthony served as development lead for FORZINITY ®, now FDA-approved for Barth Syndrome, at Stealth Biotherapeutics and led cross-functional teams across multiple rare disease programs, advanced regulatory strategy through numerous FDA Type A, B, and C meetings, and supported the company’s $78M IPO in February 2019. He also held a senior clinical development role at Merck & Co. and completed a post-doctoral fellowship at Cubist Pharmaceuticals. Anthony holds a Doctor of Pharmacy (PharmD) and a Master of Business Administration (MBA) from the University of Rhode Island, and a Master of Science in Finance (MSF) from Northeastern University.

Toby Fox is Co-Founder, Co-President, and Chief Scientific Officer of Neutrolis, and architect of its exDNASE™ platform. Following the company's Series A financing, he served as both CEO and CSO through its first clinical proof of concept in 2025, before refocusing on the CSO role. He led Neutrolis from concept to clinical validation, raising over $50M in Seed and Series A financing, building the company's founding culture, and recruiting senior leadership across Clinical, CMC, and Regulatory functions.

Trained as an immunologist, Fox earned his PhD in Immunology, summa cum laude, from Humboldt-Universität zu Berlin, conducting doctoral research in Arturo Zychlinsky's lab at the Max Planck Institute for Infection Biology alongside Neutrolis co-founder Abdul Hakkim, among the first graduate students to study the biology of neutrophil extracellular traps (NETs). He went on to a postdoctoral fellowship and instructorship at Harvard Medical School, uncovering the pathogenic role of NETs in thrombo-inflammation with Denisa Wagner. As a principal investigator at Universitätsklinikum Hamburg-Eppendorf, he identified DNASE1L3 as a master regulator of NET clearance, work published in Science in 2017 and foundational to Neutrolis’ formation.

At Neutrolis, Fox designed and led development of the exDNASE™ platform, achieving clinical validation of NET-targeting in inflammatory and immune (I&I) disease with recombinant DNASE1L3 analogs. This culminated in first-in-human proof-of-concept data, presented at the American College of Rheumatology Convergence 2025, showing rapid, multi-organ clinical improvement and strong target engagement consistent with the platform's NET-degrading mechanism, including in a treatment-refractory lupus patient with DNASE1L3 deficiency, supporting NET clearance as a disease-modifying therapeutic approach in autoimmune and inflammatory disease. He is the inventor of the company's foundational patents, spanning engineered DNASE1L3 and DNASE1 analogs, a drug development platform for extracellular DNase enzymes, and biomarkers and diagnostics for NET-driven diseases.

His work has been recognized with BMS (2017) and Pfizer (2019 and 2020) Golden Tickets at LabCentral, and a Business Insider Top Biotech Startup to Watch honor (2021). His academic contributions have earned him the Alexander Schmidt Award, the Young Talent Award for Excellence in Thrombosis, Vascular Medicine, and Hemostasis, the Eberhard F. Mammen Young Investigator Award, and a Basic Science Research Award from the Venous Disease Coalition.

Hakkim trained as an immunologist, conducting doctoral research in Arturo Zychlinsky's lab at the Max Planck Institute for Infection Biology alongside Neutrolis co-founder Toby Fox and among the first graduate students to study the biology of neutrophil extracellular traps (NETs). His research linked impaired NET degradation to lupus nephritis, helping establish the hypothesis that impaired NET clearance contributes to autoimmune pathology, work recognized with the Max Planck Society's Peter Hans Hofschneider Prize for Molecular Medicine (2011). He then completed a research fellowship at Harvard Medical School, studying innate immunity using C. elegans as a genetic model, and co-founded Genma Bio, a discovery-stage biotech venture, with Fred Ausubel.

In 2017, Hakkim co-founded Neutrolis as founding CEO, raising its seed round, building its founding team, and advancing NTR-441 to IND/CTA clearance, work recognized with BMS (2017) and Pfizer (2019 and 2020) Golden Tickets at LabCentral. He then transitioned to Chief Operating Officer, co-architecting the exDNASE™ platform alongside Toby Fox, co-leading over $50M in Seed and Series A financings, and driving execution across clinical, CMC, regulatory, and partnership functions. Under his operational leadership, Neutrolis achieved the first clinical validation of NET-targeting therapy in autoimmune disease; a milestone two decades in the making, from his earliest graduate research on NET biology to a validated therapeutic platform, culminating in first-in-human proof-of-concept data showing rapid, multi-organ clinical improvement and strong target engagement consistent with the platform's NET-degrading mechanism, including in a treatment-refractory lupus patient with DNASE1L3 deficiency, supporting NET clearance as a disease-modifying therapeutic approach in autoimmune and inflammatory disease. Neutrolis was named a Business Insider Top Biotech Startup to Watch (2021).

Andreas has extensive experience in medical leadership, with a focus on advancing treatments for autoimmune and inflammatory diseases. Prior to joining Neutrolis, Andreas served as Rheumatology Division Head at Children's Hospital Los Angeles (CHLA), University of Southern California and as Senior VP (Immunology & Inflammation) at Parexel, and founded TheraKine Ltd. At Neutrolis, he oversees clinical development and medical strategy to ensure the highest standards of medical ethics, safety and efficacy. Andreas guides the company through clinical trials, regulatory submissions, and medical affairs, with a commitment to bringing transformative treatments to market.

Caren has over 25 years of experience in the biotech industry, spanning commercial, program leadership, and C-suite roles. Most recently, she served as Chief Commercial & Strategy Officer at Editas Medicine and Magenta Therapeutics, where she was responsible for commercial and corporate strategy, as well as program and portfolio leadership.  

She spent 20 years at Biogen, including serving as Vice President of Global Product Development and as the global program and commercial lead for Spinraza®, supporting its highly successful global launch. Earlier in her tenure at Biogen, Caren played a key role in building the multiple sclerosis franchise and led U.S. and global launches of AVONEX®, TYSABRI®, and TECFIDERA®.  

Caren currently serves on the board of directors of Crinetics, Inc. She holds a B.S. in Biology from Tufts University and an MBA from the Olin Graduate School of Business at Babson College. At Neutrolis, Caren leads commercial and portfolio strategy, as well as business development.

Ralph has 25+ years of experience developing manufacturing processes and analytical methods in support of commercial, clinical and preclinical biotherapeutic products. Prior to joining Neutrolis, Ralph was VP of Biologics Operations Science & Technology at AbbVie overseeing development and commercial manufacturing of Humira® and previously held senior scientist roles at Pfizer and BASF. Ralph is a bioorganic chemist who trained at Brown University and Harvard Medical School. At Neutrolis, Ralph leads chemistry, manufacturing, and controls (CMC).

Ken has 22+ years of experience in drug development and regulatory strategy and is skilled in toxicology, regulatory affairs, and quality assurance. Ken is a drug development veteran with a history of advancing therapies across the biotechnology and pharmaceutical industries. Ken previously held positions in Regeneron, Biogen, GSK, and Merrimack Pharmaceuticals. Ken received his Bachelor’s in Toxicology from the University of Louisiana at Monroe and a PhD in Veterinary Biomedical and Clinical Sciences from Oklahoma State University. At Neutrolis, Ken oversees product development and assists with non-clinical and regulatory strategies.

Ghazaleh has 20+ years of clinical research experience and is an Associate Professor in Internal Medicine and board-certified in internal medicine, cardiology, and clinical pharmacology. Previously, Ghazaleh led a research group at the phase I Unit of the Medical University of Vienna and was Medical Director at a global CRO. She has been involved in the development and approval of numerous products and has led product strategy and protocol development by identifying and documenting the best ways to help patients. Ghazaleh and her clinical team at Gouya Insights lead Neutrolis' clinical strategy and operations.